Exelixis Inc (EXEL)

21.64
0.98 4.30
NASDAQ : Health Care
Prev Close 22.62
Open 22.72
Day Low/High 21.47 / 22.75
52 Wk Low/High 3.55 / 8.74
Volume 4.03M
Avg Volume 5.54M
Exchange NASDAQ
Shares Outstanding 286.46M
Market Cap 6.62B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Jim Cramer isn't worried about a correction: He says this recent rally isn't just about Trump's agenda. It's about profits and earnings.

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Jim Cramer is bullish on Box, Nucor, and American Airlines; but bearish on AK Steel Holdings and Rite Aid.

Hopes for Tax Reform, Less Regulation Lift Indices

Hopes for Tax Reform, Less Regulation Lift Indices

Technical indicators indicate the markets are not extended and have consolidated nicely.

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017 after the markets close.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 61,750 shares of Exelixis common stock and stock options to purchase an aggregate of 123,500...

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis, Inc. (NASDAQ:EXEL) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib,...

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round

Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Home Depot and prefers Schlumberger to SeaDrill Limited.

Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)

Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)

Crosscurrents are disruptive, and today's selloff demonstrates why investors need conviction -- and a strong stomach, says Jim Cramer.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group

Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group

Exelixis, Inc. (Nasdaq:EXEL) announced today that Genentech, Inc.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (NASDAQ:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 17,750 shares of Exelixis common stock, and stock options to purchase an aggregate of 35,500...

Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada

Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today jointly announced an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development of...

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline

Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline

Exelixis, Inc. (NASDAQ:EXEL) today announced two high-level appointments designed to further strengthen the company's public affairs and business development capabilities following the launch of its newest medicine,...

Look at Silver Miners and Some Names That Have Pulled Back

Look at Silver Miners and Some Names That Have Pulled Back

I'm feeling pressure to force some trades today, but I'm trying to stay selective.

Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14

Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Shark Bites: Eager Buyers Pounce on Pullback

Shark Bites: Eager Buyers Pounce on Pullback

I'm underinvested, which isn't good when indices are up.

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Interpreting 'K-M curves' correctly is an important tool for biotech investors.

How to Be a Smarter Biotech Investor

How to Be a Smarter Biotech Investor

Interpreting "K-M curves" correctly is an important tool for biotech investors.

Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29

Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15

Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials

Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies to treat forms of advanced melanoma.

Exelixis (EXEL) Stock Gains on Q3 Results

Exelixis (EXEL) Stock Gains on Q3 Results

Exelixis (EXEL) beat expectations for the third quarter.